{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:38:02Z","timestamp":1792802282326,"version":"4.5.0"},"reference-count":82,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The French Ministry for Europe and Foreign Affairs","award":["REPAIR COVID-19 Africa"],"award-info":[{"award-number":["REPAIR COVID-19 Africa"]}],"id":[{"id":"https:\/\/ror.org\/00dfd1509","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Coronavirus 2019 (COVID-19) is a global health threat. The kinetics of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be assessed, as the long-term duration of these immunoglobulins remains largely controversial. The aim of this study was to assess the longitudinal dynamics of anti-SARS-CoV-2 antibodies against the nucleocapsid (N) protein and the receptor-binding domain (RBD) of the spike protein up to one year in a cohort of 190 COVID-19 patients. Between March and September 2021, we enrolled patients from two regional hospitals in Casablanca, Morocco. Blood samples were collected and analyzed for antibody levels. We used the commercial Euroimmun ELISA for the determination of anti-N IgM, the Abbott Architect\n                    <jats:sup>\u2122<\/jats:sup>\n                    SARS-CoV-2 IgG test for the detection of anti-RBD IgG, and an in-house kit for the assay of anti-N IgG and anti-N IgA. IgM and IgA antibodies were assessed 2\u20135, 9\u201312, 17\u201320 and 32\u201337 days after symptom onset. IgG antibodies were also assessed 60, 90, 120 and 360 days after symptom onset. One-third of patients developed IgM (32%), while two-thirds developed IgA (61%). One month of symptom onset, most patients developed IgG, with 97% and 93% positivity for anti-RBD IgG and anti-N IgG, respectively. The anti-RBD IgG positivity rate remained high up to one year of follow-up. However, the anti-N IgG positivity rate decreased over time, with only 41% of patients testing positive after one year\u2019s follow-up. IgG levels were significantly higher in older people (over 50 years) than in other study participants. We also found that patients who had received two doses of ChAdOx1 nCoV-19 vaccine prior to infection had a lower IgM response than unvaccinated patients. This difference was statistically significant two weeks after the onset of symptoms. We present the first study in Africa to measure the kinetics of antibody response (IgA, IgM and IgG) to SARS-CoV-2 over one year. Most participants remained seropositive for anti-RBD IgG after one year but showed a significant decline in antibody titers.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0288557","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T14:04:40Z","timestamp":1689170680000},"page":"e0288557","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":39,"title":["Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study"],"prefix":"10.1371","volume":"18","author":[{"given":"Houda","family":"Amellal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najlaa","family":"Assaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Charoute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Akarid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahmane","family":"Maaroufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-6163","authenticated-orcid":true,"given":"Sayeh","family":"Ezzikouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0077","authenticated-orcid":true,"given":"M\u2019hammed","family":"Sarih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"pone.0288557.ref001","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/jcm9041225","article-title":"The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control","volume":"9","author":"YA Helmy","year":"2020","journal-title":"J Clin Med"},{"key":"pone.0288557.ref002","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"N Chen","year":"2020","journal-title":"The Lancet"},{"key":"pone.0288557.ref003","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"The Lancet"},{"key":"pone.0288557.ref004","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41577-020-00423-9","article-title":"Antibody response to SARS-CoV-2\u2014sustained after all?","volume":"20","author":"EB Compeer","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"pone.0288557.ref005","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"183","author":"AC Walls","year":"2020","journal-title":"Cell"},{"key":"pone.0288557.ref006","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2","volume":"181","author":"Q Wang","year":"2020","journal-title":"Cell"},{"key":"pone.0288557.ref007","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41467-021-22034-1","article-title":"SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19","volume":"12","author":"J Wu","year":"2021","journal-title":"Nat Commun"},{"key":"pone.0288557.ref008","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/all.14622","article-title":"Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections","volume":"76","author":"Q Lei","year":"2021","journal-title":"Allergy"},{"key":"pone.0288557.ref009","first-page":"3491","article-title":"Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19","volume":"205","author":"EH Vogelzang","year":"2020","journal-title":"J Immunol Baltim Md 1950"},{"key":"pone.0288557.ref010","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/s41467-020-19943-y","article-title":"Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19","volume":"11","author":"K Li","year":"2020","journal-title":"Nat Commun"},{"key":"pone.0288557.ref011","first-page":"1557.e1","article-title":"Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs","volume":"26","author":"J Van Elslande","year":"2020","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"pone.0288557.ref012","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Q-X Long","year":"2020","journal-title":"Nat Med"},{"key":"pone.0288557.ref013","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals","volume":"52","author":"L Ni","year":"2020","journal-title":"Immunity"},{"key":"pone.0288557.ref014","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1099\/jgv.0.001439","article-title":"The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection","volume":"101","author":"P Kellam","year":"2020","journal-title":"J Gen Virol"},{"key":"pone.0288557.ref015","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamainternmed.2020.4616","article-title":"Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China","volume":"180","author":"F Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"pone.0288557.ref016","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/v12121390","article-title":"Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients","volume":"12","author":"AM Hashem","year":"2020","journal-title":"Viruses"},{"key":"pone.0288557.ref017","doi-asserted-by":"crossref","first-page":"eabe0240","DOI":"10.1126\/sciimmunol.abe0240","article-title":"Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome","volume":"5","author":"K R\u00f6ltgen","year":"2020","journal-title":"Sci Immunol"},{"key":"pone.0288557.ref018","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3390\/microorganisms8121885","article-title":"Anti\u2013SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study","volume":"8","author":"E Terpos","year":"2020","journal-title":"Microorganisms"},{"key":"pone.0288557.ref019","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"J Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"pone.0288557.ref020","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-021-01355-0","article-title":"Delayed production of neutralizing antibodies correlates with fatal COVID-19","volume":"27","author":"C Lucas","year":"2021","journal-title":"Nat Med"},{"key":"pone.0288557.ref021","doi-asserted-by":"crossref","first-page":"eabe5511","DOI":"10.1126\/sciimmunol.abe5511","article-title":"Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients","volume":"5","author":"B Isho","year":"2020","journal-title":"Sci Immunol"},{"key":"pone.0288557.ref022","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid Decay of Anti\u2013SARS-CoV-2 Antibodies in Persons with Mild Covid-19","volume":"383","author":"FJ Ibarrondo","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0288557.ref023","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00284-022-02800-0","article-title":"Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies","volume":"79","author":"Z Yousefi","year":"2022","journal-title":"Curr Microbiol"},{"key":"pone.0288557.ref024","doi-asserted-by":"crossref","first-page":"1152522","DOI":"10.3389\/fimmu.2023.1152522","article-title":"Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months","volume":"14","author":"J Serwanga","year":"2023","journal-title":"Front Immunol"},{"key":"pone.0288557.ref025","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.xcrm.2021.100290","article-title":"Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset","volume":"2","author":"SP Anand","year":"2021","journal-title":"Cell Rep Med"},{"key":"pone.0288557.ref026","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"A Wajnberg","year":"2020","journal-title":"Science"},{"key":"pone.0288557.ref027","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijid.2022.11.025","article-title":"SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions","volume":"126","author":"D Mioch","year":"2023","journal-title":"Int J Infect Dis"},{"key":"pone.0288557.ref028","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"JM Dan","year":"2021","journal-title":"Science"},{"key":"pone.0288557.ref029","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","article-title":"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)","volume":"397","author":"VJ Hall","year":"2021","journal-title":"The Lancet"},{"key":"pone.0288557.ref030","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study","volume":"397","author":"CH Hansen","year":"2021","journal-title":"The Lancet"},{"key":"pone.0288557.ref031","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers","volume":"384","author":"SF Lumley","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0288557.ref032","doi-asserted-by":"crossref","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"NG Davies","year":"2021","journal-title":"Science"},{"key":"pone.0288557.ref033","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"H Tegally","year":"2021","journal-title":"Nature"},{"key":"pone.0288557.ref034","doi-asserted-by":"crossref","first-page":"115903","DOI":"10.1016\/j.diagmicrobio.2023.115903","article-title":"Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings","volume":"105","author":"C Benabdessalem","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"pone.0288557.ref035","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/clinchem\/hvaa120","article-title":"Clinical performance of two SARS-CoV-2 serologic assays","volume":"66","author":"MS Tang","year":"2020","journal-title":"Clin Chem"},{"key":"pone.0288557.ref036","doi-asserted-by":"crossref","first-page":"e02596","DOI":"10.1128\/JCM.02596-20","article-title":"Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories","volume":"59","author":"LH Harritsh\u00f8j","year":"2021","journal-title":"J Clin Microbiol"},{"key":"pone.0288557.ref037","doi-asserted-by":"crossref","first-page":"e00288","DOI":"10.1128\/JCM.00288-21","article-title":"Performance of the Abbott SARS-CoV-2 IgG II quantitative antibody assay including the new variants of concern, VOC 202012\/V1 (United Kingdom) and VOC 202012\/V2 (South Africa), and first steps towards global harmonization of COVID-19 antibody methods","volume":"59","author":"E English","year":"2021","journal-title":"J Clin Microbiol"},{"key":"pone.0288557.ref038","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/cbin.11516","article-title":"Serological tests for COVID\u201019: Potential opportunities","volume":"45","author":"MM Tantuoyir","year":"2021","journal-title":"Cell Biol Int"},{"key":"pone.0288557.ref039","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cca.2020.09.033","article-title":"SARS-CoV-2 infection serology validation of different methods: Usefulness of IgA in the early phase of infection","volume":"511","author":"M Pieri","year":"2020","journal-title":"Clin Chim Acta"},{"key":"pone.0288557.ref040","doi-asserted-by":"crossref","first-page":"104663","DOI":"10.1016\/j.jcv.2020.104663","article-title":"Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect","volume":"133","author":"GN Maine","year":"2020","journal-title":"J Clin Virol"},{"key":"pone.0288557.ref041","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cca.2020.04.026","article-title":"IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study","volume":"507","author":"A Padoan","year":"2020","journal-title":"Clin Chim Acta"},{"key":"pone.0288557.ref042","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4269\/ajtmh.22-0448","article-title":"Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients","volume":"108","author":"N Assaid","year":"2023","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0288557.ref043","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/v13061115","article-title":"The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation","volume":"13","author":"Z Bai","year":"2021","journal-title":"Viruses"},{"key":"pone.0288557.ref044","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12866-021-02401-0","article-title":"IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients","volume":"21","author":"L Yang","year":"2021","journal-title":"BMC Microbiol"},{"key":"pone.0288557.ref045","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3390\/v13101945","article-title":"IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases","volume":"13","author":"M Tutukina","year":"2021","journal-title":"Viruses"},{"key":"pone.0288557.ref046","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1074-7613(03)00323-6","article-title":"Activation of autoreactive B cells by CpG dsDNA","volume":"19","author":"GA Viglianti","year":"2003","journal-title":"Immunity"},{"key":"pone.0288557.ref047","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/416603a","article-title":"Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors","volume":"416","author":"EA Leadbetter","year":"2002","journal-title":"Nature"},{"key":"pone.0288557.ref048","doi-asserted-by":"crossref","first-page":"103561","DOI":"10.1016\/j.ebiom.2021.103561","article-title":"Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection","volume":"71","author":"F Gallais","year":"2021","journal-title":"EBioMedicine"},{"key":"pone.0288557.ref049","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1172\/JCI138759","article-title":"Kinetics of viral load and antibody response in relation to COVID-19 severity","volume":"130","author":"Y Wang","year":"2020","journal-title":"J Clin Invest"},{"key":"pone.0288557.ref050","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Q-X Long","year":"2020","journal-title":"Nat Med"},{"key":"pone.0288557.ref051","first-page":"24","article-title":"Severe, symptomatic reinfection in a patient with COVID-19","volume":"103","author":"V Selvaraj","year":"2020","journal-title":"RI Med J"},{"key":"pone.0288557.ref052","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1473-3099(20)30764-7","article-title":"Genomic evidence for reinfection with SARS-CoV-2: a case study","volume":"21","author":"RL Tillett","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"pone.0288557.ref053","first-page":"e2946","article-title":"COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing","volume":"73","author":"KK To","year":"2021","journal-title":"Clin Infect Dis"},{"key":"pone.0288557.ref054","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.7861\/clinmed.2020-0912","article-title":"A case of COVID-19 reinfection in the UK","volume":"21","author":"J West","year":"2021","journal-title":"Clin Med"},{"key":"pone.0288557.ref055","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/s41598-022-06038-5","article-title":"Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection","volume":"12","author":"M Choteau","year":"2022","journal-title":"Sci Rep"},{"key":"pone.0288557.ref056","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11739-021-02750-8","article-title":"Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital","volume":"17","author":"A Carnicelli","year":"2022","journal-title":"Intern Emerg Med"},{"key":"pone.0288557.ref057","doi-asserted-by":"crossref","first-page":"108491","DOI":"10.1016\/j.intimp.2021.108491","article-title":"Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers","volume":"103","author":"M Kurano","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"pone.0288557.ref058","doi-asserted-by":"crossref","first-page":"e0281689","DOI":"10.1371\/journal.pone.0281689","article-title":"Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals","volume":"18","author":"M Al-Tamimi","year":"2023","journal-title":"PLOS ONE"},{"key":"pone.0288557.ref059","doi-asserted-by":"crossref","first-page":"eabf1555","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Z Wang","year":"2021","journal-title":"Sci Transl Med"},{"key":"pone.0288557.ref060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.idnow.2022.01.004","article-title":"Evolution of anti-SARS-CoV-2 immune response in a cohort of French healthcare workers followed for 7 months","volume":"52","author":"B Pilmis","year":"2022","journal-title":"Infect Dis Now"},{"key":"pone.0288557.ref061","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","article-title":"Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19","volume":"12","author":"AK Wheatley","year":"2021","journal-title":"Nat Commun"},{"key":"pone.0288557.ref062","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.kint.2021.04.018","article-title":"Disparity between levels of anti-RBD IgG and anti-nucleocapsid protein IgG antibodies in COVID-19\u2013recovered patients who received a kidney transplant","volume":"100","author":"C-C Chang","year":"2021","journal-title":"Kidney Int"},{"key":"pone.0288557.ref063","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.3390\/v14071491","article-title":"Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination","volume":"14","author":"L Garcia","year":"2022","journal-title":"Viruses"},{"key":"pone.0288557.ref064","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Y Yang","year":"2022","journal-title":"Nat Microbiol"},{"key":"pone.0288557.ref065","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3892\/etm.2022.11318","article-title":"Clinical significance of early IgA anti-SARS-CoV-2 antibody detection in patients from a Romanian referral COVID-19 hospital","volume":"23","author":"A V\u00e2\u0163\u0103","year":"2022","journal-title":"Exp Ther Med"},{"key":"pone.0288557.ref066","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1038\/s41467-020-17318-x","article-title":"Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital","volume":"11","author":"AL Garcia-Basteiro","year":"2020","journal-title":"Nat Commun"},{"key":"pone.0288557.ref067","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3724\/abbs.2022014","article-title":"SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages","volume":"54","author":"L Lu","year":"2022","journal-title":"Acta Biochim Biophys Sin"},{"key":"pone.0288557.ref068","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejim.2022.02.010","article-title":"Reduced COVID-19 mortality linked with early antibodies against SARS-CoV-2, irrespective of age","volume":"98","author":"D De Vito","year":"2022","journal-title":"Eur J Intern Med"},{"key":"pone.0288557.ref069","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jinf.2020.08.032","article-title":"SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on","volume":"82","author":"W Korte","year":"2021","journal-title":"J Infect"},{"key":"pone.0288557.ref070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/ijerph19010042","article-title":"Demographic and clinical factors associated with reactivity of anti-SARS-CoV-2 antibodies in serbian convalescent plasma donors","volume":"19","author":"J Gruji\u0107","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"pone.0288557.ref071","first-page":"239","article-title":"Sex differences in vaccine-induced humoral immunity. Seminars in immunopathology","volume":"41","author":"S Fischinger","year":"2019","journal-title":"Springer"},{"key":"pone.0288557.ref072","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","article-title":"Considering how biological sex impacts immune responses and COVID-19 outcomes","volume":"20","author":"EP Scully","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"pone.0288557.ref073","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijid.2021.04.078","article-title":"Dynamic changes and prevalence of SARS-CoV-2 IgG\/IgM antibodies: Analysis of multiple factors","volume":"108","author":"C Luo","year":"2021","journal-title":"Int J Infect Dis"},{"key":"pone.0288557.ref074","doi-asserted-by":"crossref","first-page":"793191","DOI":"10.3389\/fimmu.2021.793191","article-title":"Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History","volume":"12","author":"M Tarkowski","year":"2021","journal-title":"Front Immunol"},{"key":"pone.0288557.ref075","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"SJ Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0288557.ref076","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/ajt.16775","article-title":"Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients","volume":"22","author":"A Del Bello","year":"2022","journal-title":"Am J Transplant"},{"key":"pone.0288557.ref077","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1","volume":"398","author":"M Shrotri","year":"2021","journal-title":"The Lancet"},{"key":"pone.0288557.ref078","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/vaccines11010188","article-title":"Anti-SARS-CoV-2 IgM Secondary Response Was Suppressed by Preexisting Immunity in Vaccinees: A Prospective, Longitudinal Cohort Study over 456 Days","volume":"11","author":"Q-Y Xu","year":"2023","journal-title":"Vaccines"},{"key":"pone.0288557.ref079","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"S Feng","year":"2021","journal-title":"Nat Med"},{"key":"pone.0288557.ref080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"PB Gilbert","year":"2022","journal-title":"Science"},{"key":"pone.0288557.ref081","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"L Piccoli","year":"2020","journal-title":"Cell"},{"key":"pone.0288557.ref082","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1172\/JCI141206","article-title":"Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization","volume":"130","author":"E Salazar","year":"2020","journal-title":"J Clin Invest"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0288557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T14:05:26Z","timestamp":1689170726000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0288557"}},"subtitle":[],"editor":[{"given":"Vittorio","family":"Sambri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":82,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0288557","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]}}}